Lung cancer kills more Americans each year than any other cancer — yet most Americans are uninformed about this disease. A ...

Microgravity experiments on the International Space Station helped Merck develop a faster subcutaneous version of Keytruda (pembrolizumab). This new injection cuts treatment time to minutes, improving ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Rio Tinto and Glencore previously held deal talks in late 2024, but they ended over issues including valuation, the chief ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

An Auckland woman who is self-funding treatment for her rare, aggressive breast cancer is fed up after years of asking the government to fund a "life-saving" medicine for more patients.

Forbes contributors publish independent expert analyses and insights. Dr. Tracy Brower writes about joy, community and the future of work. This voice experience is generated by AI. Learn more. This ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to counter sales cliffs for two of its biggest drugs. Merck has been vocal ...